Amount Raised
$2 Million
Round Type
seed
Description
Symvivo Corporation today announced that it is receiving advisory services and funding of up to $2.8 million from the National Research Council Industrial Research Assistance Program (NRC IRAP) to support the clinical advancement of bacTRL-Spike™, the company’s oral, room temperature-stable DNA vaccine candidate for the prevention of COVID-19.
FundzWatch™ Score
89
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood